'Wednesday, Biogen said it's pulling all efforts from the first-of-its-kind anti-amyloid beta therapy to focus on Leqembi, its Eisai-partnered newer medicine, and its pipeline candidates. The newer drug, Leqembi, won a full FDA approval early last year, making the partners' marketing efforts on the therapy much simpler than was the case with Aduhelm.'

https://www.fiercepharma.com/pharma/biogen-abandons-aduhelm-efforts-focuses-eisai-partnered-leqembi-and-pipeline-meds